PATENT CLAIM ANALYSIS

Application Number: 16158738
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-06
Patent Classification: ["514", "546000"]

Abstract:
Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.

Claim (Index 21):
A liquid oral pharmaceutical formulation suitable for treating a human subject with an endogenous 11-cis-retinal deficiency consisting essentially of 9-cis-retinyl acetate in soybean oil and an anti-oxidant, wherein said formulation is not in the form of a capsule.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: half
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15274257', '13090215', '14875342', '13619731', '13619631']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7756062429165874
- 35 USC 102 Novelty (BERT): 0.6616219470378218
- Combined Prediction Score: 0.7642078133287108
- Mean Citation Score: 426.782604
- Max Citation Score: 639.7981
- Similarity Product: 624.3566913859904

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test